Morton, G., Chung, H. T., McGuffin, M., Helou, J., D'Alimonte, L., Ravi, A., Cheung, P., Szumacher, E., Liu, S., Al-Hanaqta, M., Zhang, L., Mamedov, A., & Loblaw, A. (n.d.). prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Radiotherapy and oncology, 122(1), 87–92. http://access.bl.uk/ark:/81055/vdc_100041287731.0x000050